TY - JOUR AU - Herrmann, K. PY - 2015 DA - 2015// TI - Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective JO - J Nucl Med VL - 56 UR - https://doi.org/10.2967/jnumed.114.148247 DO - 10.2967/jnumed.114.148247 ID - Herrmann2015 ER - TY - JOUR AU - Kulke, M. H. PY - 2012 DA - 2012// TI - Neuroendocrine tumors JO - J Natl Compr Cancer Netw VL - 10 UR - https://doi.org/10.6004/jnccn.2012.0075 DO - 10.6004/jnccn.2012.0075 ID - Kulke2012 ER - TY - JOUR AU - Pavel, M. PY - 2016 DA - 2016// TI - ENETS consensus guidelines update for the Management of Distant Metastatic Disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site JO - Neuroendocrinology VL - 103 UR - https://doi.org/10.1159/000443167 DO - 10.1159/000443167 ID - Pavel2016 ER - TY - JOUR AU - Hope, T. A. PY - 2015 DA - 2015// TI - Simultaneous (68) Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor JO - Abdom Imaging VL - 40 UR - https://doi.org/10.1007/s00261-015-0409-9 DO - 10.1007/s00261-015-0409-9 ID - Hope2015 ER - TY - JOUR AU - Kumar, R. PY - 2011 DA - 2011// TI - Role of (68) Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours JO - Eur Radiol VL - 21 UR - https://doi.org/10.1007/s00330-011-2199-y DO - 10.1007/s00330-011-2199-y ID - Kumar2011 ER - TY - JOUR AU - Beiderwellen, K. J. PY - 2013 DA - 2013// TI - Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results JO - Investig Radiol VL - 48 UR - https://doi.org/10.1097/RLI.0b013e3182871a7f DO - 10.1097/RLI.0b013e3182871a7f ID - Beiderwellen2013 ER - TY - JOUR AU - Schraml, C. PY - 2013 DA - 2013// TI - Staging of neuroendocrine tumours: comparison of [(6, 8) Ga] DOTATOC multiphase PET/CT and whole-body MRI JO - Cancer Imaging VL - 13 UR - https://doi.org/10.1102/1470-7330.2013.0007 DO - 10.1102/1470-7330.2013.0007 ID - Schraml2013 ER - TY - JOUR AU - Sawicki, L. M. PY - 2017 DA - 2017// TI - Evaluation of (68) Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with (68) Ga-DOTATOC PET/CT JO - Eur Radiol VL - 27 UR - https://doi.org/10.1007/s00330-017-4803-2 DO - 10.1007/s00330-017-4803-2 ID - Sawicki2017 ER - TY - JOUR AU - Schmid-Tannwald, C. PY - 2013 DA - 2013// TI - Diffusion-weighted MRI of the abdomen: current value in clinical routine JO - J Magn Reson Imaging VL - 37 UR - https://doi.org/10.1002/jmri.23643 DO - 10.1002/jmri.23643 ID - Schmid-Tannwald2013 ER - TY - JOUR AU - Thoeny, H. C. AU - Ross, B. D. PY - 2010 DA - 2010// TI - Predicting and monitoring cancer treatment response with diffusion-weighted MRI JO - J Magn Reson Imaging VL - 32 UR - https://doi.org/10.1002/jmri.22167 DO - 10.1002/jmri.22167 ID - Thoeny2010 ER - TY - JOUR AU - Perez-Lopez, R. PY - 2017 DA - 2017// TI - Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate Cancer: a pilot study JO - Radiology VL - 283 UR - https://doi.org/10.1148/radiol.2016160646 DO - 10.1148/radiol.2016160646 ID - Perez-Lopez2017 ER - TY - JOUR AU - Schmainda, K. M. PY - 2012 DA - 2012// TI - Diffusion-weighted MRI as a biomarker for treatment response in glioma JO - CNS Oncol VL - 1 UR - https://doi.org/10.2217/cns.12.25 DO - 10.2217/cns.12.25 ID - Schmainda2012 ER - TY - JOUR AU - Oberg, K. AU - Eriksson, B. PY - 2005 DA - 2005// TI - Endocrine tumours of the pancreas JO - Best Pract Res Clin Gastroenterol VL - 19 UR - https://doi.org/10.1016/j.bpg.2005.06.002 DO - 10.1016/j.bpg.2005.06.002 ID - Oberg2005 ER - TY - JOUR AU - Frilling, A. PY - 2010 DA - 2010// TI - Multimodal management of neuroendocrine liver metastases JO - HPB (Oxford) VL - 12 UR - https://doi.org/10.1111/j.1477-2574.2010.00175.x DO - 10.1111/j.1477-2574.2010.00175.x ID - Frilling2010 ER - TY - JOUR AU - Modlin, I. M. AU - Lye, K. D. AU - Kidd, M. PY - 2003 DA - 2003// TI - A 5-decade analysis of 13,715 carcinoid tumors JO - Cancer VL - 97 UR - https://doi.org/10.1002/cncr.11105 DO - 10.1002/cncr.11105 ID - Modlin2003 ER - TY - JOUR AU - Hutchinson, L. PY - 2014 DA - 2014// TI - Neuroendocrine cancer: CLARINET: new option for NETs JO - Nat Rev Clin Oncol VL - 11 UR - https://doi.org/10.1038/nrclinonc.2014.131 DO - 10.1038/nrclinonc.2014.131 ID - Hutchinson2014 ER - TY - JOUR AU - Rinke, A. PY - 2009 DA - 2009// TI - Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.22.8510 DO - 10.1200/JCO.2009.22.8510 ID - Rinke2009 ER - TY - JOUR AU - Caplin, M. E. AU - Pavel, M. AU - Ruszniewski, P. PY - 2014 DA - 2014// TI - Lanreotide in metastatic enteropancreatic neuroendocrine tumors JO - N Engl J Med VL - 371 ID - Caplin2014 ER - TY - JOUR AU - Raymond, E. PY - 2011 DA - 2011// TI - Sunitinib malate for the treatment of pancreatic neuroendocrine tumors JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1003825 DO - 10.1056/NEJMoa1003825 ID - Raymond2011 ER - TY - JOUR AU - Yao, J. C. PY - 2011 DA - 2011// TI - Everolimus for advanced pancreatic neuroendocrine tumors JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1009290 DO - 10.1056/NEJMoa1009290 ID - Yao2011 ER - TY - JOUR AU - Welin, S. PY - 2011 DA - 2011// TI - Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy JO - Cancer VL - 117 UR - https://doi.org/10.1002/cncr.26124 DO - 10.1002/cncr.26124 ID - Welin2011 ER - TY - JOUR AU - Moertel, C. G. PY - 1992 DA - 1992// TI - Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma JO - N Engl J Med VL - 326 UR - https://doi.org/10.1056/NEJM199202203260804 DO - 10.1056/NEJM199202203260804 ID - Moertel1992 ER - TY - JOUR AU - Rivera, E. AU - Ajani, J. A. PY - 1998 DA - 1998// TI - Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma JO - Am J Clin Oncol VL - 21 UR - https://doi.org/10.1097/00000421-199802000-00008 DO - 10.1097/00000421-199802000-00008 ID - Rivera1998 ER - TY - JOUR AU - Kouvaraki, M. A. PY - 2004 DA - 2004// TI - Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.04.024 DO - 10.1200/JCO.2004.04.024 ID - Kouvaraki2004 ER - TY - JOUR AU - Strosberg, J. R. PY - 2011 DA - 2011// TI - First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas JO - Cancer VL - 117 UR - https://doi.org/10.1002/cncr.25425 DO - 10.1002/cncr.25425 ID - Strosberg2011 ER - TY - JOUR AU - Fine, R. L. PY - 2013 DA - 2013// TI - Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the pancreas Center at Columbia University experience JO - Cancer Chemother Pharmacol VL - 71 UR - https://doi.org/10.1007/s00280-012-2055-z DO - 10.1007/s00280-012-2055-z ID - Fine2013 ER - TY - JOUR AU - Peixoto, R. D. PY - 2014 DA - 2014// TI - Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs JO - J Gastrointest Oncol VL - 5 ID - Peixoto2014 ER - TY - JOUR AU - Cives, M. PY - 2016 DA - 2016// TI - Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors JO - Endocr Relat Cancer VL - 23 UR - https://doi.org/10.1530/ERC-16-0147 DO - 10.1530/ERC-16-0147 ID - Cives2016 ER - TY - JOUR AU - Strosberg, J. PY - 2017 DA - 2017// TI - Phase 3 trial of (177) Lu-Dotatate for Midgut neuroendocrine tumors JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1607427 DO - 10.1056/NEJMoa1607427 ID - Strosberg2017 ER - TY - JOUR AU - Haug, A. R. PY - 2010 DA - 2010// TI - 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors JO - J Nucl Med VL - 51 UR - https://doi.org/10.2967/jnumed.110.075002 DO - 10.2967/jnumed.110.075002 ID - Haug2010 ER - TY - JOUR AU - Oksuz, M. O. PY - 2014 DA - 2014// TI - Peptide receptor radionuclide therapy of neuroendocrine tumors with (90) Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68) Ga-DOTATOC? JO - Diagn Interv Imaging VL - 95 UR - https://doi.org/10.1016/j.diii.2013.07.006 DO - 10.1016/j.diii.2013.07.006 ID - Oksuz2014 ER - TY - JOUR AU - Tixier, F. PY - 2011 DA - 2011// TI - Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer JO - J Nucl Med VL - 52 UR - https://doi.org/10.2967/jnumed.110.082404 DO - 10.2967/jnumed.110.082404 ID - Tixier2011 ER - TY - JOUR AU - Cook, G. J. PY - 2015 DA - 2015// TI - Non-small cell lung Cancer treated with Erlotinib: heterogeneity of (18) F-FDG uptake at PET-association with treatment response and prognosis JO - Radiology VL - 276 UR - https://doi.org/10.1148/radiol.2015141309 DO - 10.1148/radiol.2015141309 ID - Cook2015 ER - TY - JOUR AU - Cook, G. J. PY - 2013 DA - 2013// TI - Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? JO - J Nucl Med VL - 54 UR - https://doi.org/10.2967/jnumed.112.107375 DO - 10.2967/jnumed.112.107375 ID - Cook2013 ER - TY - JOUR AU - Eisenhauer, E. A. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Virgolini, I. PY - 2010 DA - 2010// TI - Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE JO - Eur J Nucl Med Mol Imaging VL - 37 UR - https://doi.org/10.1007/s00259-010-1512-3 DO - 10.1007/s00259-010-1512-3 ID - Virgolini2010 ER - TY - JOUR AU - Bozkurt, M. F. PY - 2017 DA - 2017// TI - Guideline for PET/CT imaging of neuroendocrine neoplasms with (68) Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18) F-DOPA JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3728-y DO - 10.1007/s00259-017-3728-y ID - Bozkurt2017 ER - TY - JOUR AU - Haug, A. R. PY - 2011 DA - 2011// TI - Treatment with octreotide does not reduce tumor uptake of (68) Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors JO - J Nucl Med VL - 52 UR - https://doi.org/10.2967/jnumed.111.089276 DO - 10.2967/jnumed.111.089276 ID - Haug2011 ER - TY - JOUR AU - Delso, G. PY - 2011 DA - 2011// TI - Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner JO - J Nucl Med VL - 52 UR - https://doi.org/10.2967/jnumed.111.092726 DO - 10.2967/jnumed.111.092726 ID - Delso2011 ER - TY - JOUR AU - Nioche, C. PY - 2018 DA - 2018// TI - LIFEx: a freeware for Radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity JO - Cancer Res VL - 78 UR - https://doi.org/10.1158/0008-5472.CAN-18-0125 DO - 10.1158/0008-5472.CAN-18-0125 ID - Nioche2018 ER - TY - JOUR AU - Cheng, N. M. PY - 2019 DA - 2019// TI - Prognostic value of tumor heterogeneity and SUVmax of pretreatment 18F-FDG PET/CT for salivary gland carcinoma with high-risk histology JO - Clin Nucl Med VL - 44 UR - https://doi.org/10.1097/RLU.0000000000002530 DO - 10.1097/RLU.0000000000002530 ID - Cheng2019 ER - TY - JOUR AU - Bashir, U. PY - 2018 DA - 2018// TI - Investigating the histopathologic correlates of 18F-FDG PET heterogeneity in non-small-cell lung cancer JO - Nucl Med Commun VL - 39 UR - https://doi.org/10.1097/MNM.0000000000000925 DO - 10.1097/MNM.0000000000000925 ID - Bashir2018 ER - TY - JOUR AU - Choi, J. PY - 2019 DA - 2019// TI - Association of metabolic and genetic heterogeneity in head and neck squamous cell carcinoma with prognostic implications: integration of FDG PET and genomic analysis JO - EJNMMI Res VL - 9 UR - https://doi.org/10.1186/s13550-019-0563-0 DO - 10.1186/s13550-019-0563-0 ID - Choi2019 ER - TY - JOUR AU - McDonald, J. E. PY - 2017 DA - 2017// TI - Assessment of Total lesion glycolysis by (18) F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-0235 DO - 10.1158/1078-0432.CCR-16-0235 ID - McDonald2017 ER - TY - JOUR AU - Zhao, Y. PY - 2018 DA - 2018// TI - Prognostic value of tumor heterogeneity on 18F-FDG PET/CT in HR+HER2- metastatic breast Cancer patients receiving 500 mg Fulvestrant: a retrospective study JO - Sci Rep VL - 8 UR - https://doi.org/10.1038/s41598-018-32745-z DO - 10.1038/s41598-018-32745-z ID - Zhao2018 ER - TY - JOUR AU - Plouin, P. F. PY - 2016 DA - 2016// TI - European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma JO - Eur J Endocrinol VL - 174 UR - https://doi.org/10.1530/EJE-16-0033 DO - 10.1530/EJE-16-0033 ID - Plouin2016 ER - TY - JOUR AU - Kostakoglu, L. AU - Goldsmith, S. J. PY - 2003 DA - 2003// TI - 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma JO - J Nucl Med VL - 44 ID - Kostakoglu2003 ER - TY - JOUR AU - Weber, W. A. PY - 2003 DA - 2003// TI - Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.12.004 DO - 10.1200/JCO.2003.12.004 ID - Weber2003 ER - TY - JOUR AU - Wieder, H. A. PY - 2004 DA - 2004// TI - Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.07.122 DO - 10.1200/JCO.2004.07.122 ID - Wieder2004 ER - TY - STD TI - Lue KH, et al. Intratumor heterogeneity assessed by (18) F-FDG PET/CT predicts treatment response and survival outcomes in patients with Hodgkin lymphoma. Acad Radiol. 2019. https://doi.org/10.1016/j.acra.2019.10.015. [Epub ahead of print]. ID - ref50 ER - TY - JOUR AU - Huang, Y. S. PY - 2019 DA - 2019// TI - Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography JO - Strahlenther Onkol VL - 195 UR - https://doi.org/10.1007/s00066-018-1418-8 DO - 10.1007/s00066-018-1418-8 ID - Huang2019 ER - TY - STD TI - Werner RA, et al. Pre-therapy Somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2018;21(3):582–90. https://doi.org/10.1007/s11307-018-1252-5. ID - ref52 ER - TY - JOUR AU - Hellman, P. PY - 2002 DA - 2002// TI - Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases JO - World J Surg VL - 26 UR - https://doi.org/10.1007/s00268-002-6630-z DO - 10.1007/s00268-002-6630-z ID - Hellman2002 ER - TY - JOUR AU - Wangberg, B. PY - 1996 DA - 1996// TI - Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction JO - World J Surg VL - 20 UR - https://doi.org/10.1007/s002689900136 DO - 10.1007/s002689900136 ID - Wangberg1996 ER -